Due to the unselective elimination of normal T cells and malignant cells, pan-T cell antigen-targeting CAR-T cells, such as CD5, CD7, and CD3 T cells17–20,30, will most likely be useful as a temporary tumor burden-control strategy instead of a permanent treatment option. The gene discussed is CD7; the disease is neoplasm.